{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:45:07Z","timestamp":1793112307327,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009673","name":"Gun och Bertil Stohnes Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009673","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n-stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-01083"],"award-info":[{"award-number":["2021-01083"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2021-03524"],"award-info":[{"award-number":["2021-03524"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2016\u201304050"],"award-info":[{"award-number":["2016\u201304050"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001858","name":"VINNOVA","doi-asserted-by":"publisher","award":["2016\u201304050"],"award-info":[{"award-number":["2016\u201304050"]}],"id":[{"id":"10.13039\/501100001858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007435","name":"\u00c5ke Wiberg Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007435","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007464","name":"Torsten S\u00f6derbergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007464","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Brain-directed immunotherapy is a promising strategy to target amyloid-\u03b2 (A\u03b2) deposits in Alzheimer\u2019s disease (AD). In the present study, we compared the therapeutic efficacy of the A\u03b2 protofibril targeting antibody RmAb158 with its bispecific variant RmAb158-scFv8D3, which enters the brain by transferrin receptor-mediated transcytosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p><jats:italic>App<\/jats:italic><jats:sup><jats:italic>NL\u2212G\u2212F<\/jats:italic><\/jats:sup>knock-in mice received RmAb158, RmAb158-scFv8D3, or PBS in three treatment regimens. First, to assess the acute therapeutic effect, a single antibody dose was given to 5\u00a0months old<jats:italic>App<\/jats:italic><jats:sup><jats:italic>NL\u2212G\u2212F<\/jats:italic><\/jats:sup>mice, with evaluation after 3\u00a0days. Second, to assess the antibodies\u2019 ability to halt the progression of A\u03b2 pathology, 3\u00a0months old<jats:italic>App<\/jats:italic><jats:sup><jats:italic>NL\u2212G\u2212F<\/jats:italic><\/jats:sup>mice received three doses during a week, with evaluation after 2\u00a0months. Reduction of RmAb158-scFv8D3 immunogenicity was explored by introducing mutations in the antibody or by depletion of CD4<jats:sup>+<\/jats:sup>T cells. Third, to study the effects of chronic treatment, 7-month-old<jats:italic>App<\/jats:italic><jats:sup><jats:italic>NL\u2212G\u2212F<\/jats:italic><\/jats:sup>mice were CD4<jats:sup>+<\/jats:sup>T cell depleted and treated with weekly antibody injections for 8\u00a0weeks, including a final diagnostic dose of [<jats:sup>125<\/jats:sup>I]RmAb158-scFv8D3, to determine its brain uptake ex vivo. Soluble A\u03b2 aggregates and total A\u03b242 were quantified with ELISA and immunostaining.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Neither RmAb158-scFv8D3 nor RmAb158 reduced soluble A\u03b2 protofibrils or insoluble A\u03b21-42 after a single injection treatment. After three successive injections, A\u03b21-42 was reduced in mice treated with RmAb158, with a similar trend in RmAb158-scFv8D3-treated mice. Bispecific antibody immunogenicity was somewhat reduced by directed mutations, but CD4<jats:sup>+<\/jats:sup>T cell depletion was used for long-term therapy. CD4<jats:sup>+<\/jats:sup>T cell-depleted mice, chronically treated with RmAb158-scFv8D3, showed a dose-dependent increase in blood concentration of the diagnostic [<jats:sup>125<\/jats:sup>I]RmAb158-scFv8D3, while concentration was low in plasma and brain. Chronic treatment did not affect soluble A\u03b2 aggregates, but a reduction in total A\u03b242 was seen in the cortex of mice treated with both antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Both RmAb158 and its bispecific variant RmAb158-scFv8D3 achieved positive effects of long-term treatment. Despite its ability to efficiently enter the brain, the benefit of using the bispecific antibody in chronic treatment was limited by its reduced plasma exposure, which may be a result of interactions with TfR or the immune system. Future research will focus in new antibody formats to further improve A\u03b2 immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-023-01236-3","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T11:01:57Z","timestamp":1683025317000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Long-term effects of immunotherapy with a brain penetrating A\u03b2 antibody in a mouse model of Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"15","author":[{"given":"Tobias","family":"Gustavsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole G.","family":"Metzendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Roshanbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika","family":"Julku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Chourlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken G.","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Laudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Hultqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Syv\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dag","family":"Sehlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,2]]},"reference":[{"key":"1236_CR1","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, Dunstan R, Salloway S, Chen T, Ling Y, O\u2019Gorman J, Qian F, Arastu M, Li M, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"1236_CR2","doi-asserted-by":"crossref","unstructured":"Soderberg L, Johannesson M, Nygren P, Laudon H, Eriksson F, Osswald G, et al. Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics. 2023;20:195\u2013206.","DOI":"10.1007\/s13311-022-01308-6"},{"key":"1236_CR3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1471-4159.2007.04759.x","volume":"103","author":"H Englund","year":"2007","unstructured":"Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103:334\u201345.","journal-title":"J Neurochem"},{"key":"1236_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. Lecanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1236_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s13195-022-01129-x","volume":"14","author":"S Dhadda","year":"2022","unstructured":"Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M, Berry S, Kramer LD, Berry DA. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14:182.","journal-title":"Alzheimers Res Ther"},{"key":"1236_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s13195-022-01124-2","volume":"14","author":"E McDade","year":"2022","unstructured":"McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. Lecanemab in patients with early Alzheimer\u2019s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14:191.","journal-title":"Alzheimers Res Ther"},{"key":"1236_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"1236_CR8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/JAD-2011-110977","volume":"28","author":"B Bohrmann","year":"2012","unstructured":"Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis. 2012;28:49\u201369.","journal-title":"J Alzheimers Dis"},{"key":"1236_CR9","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, Shcherbinin S, Sparks J, Sims JR, Brys M, Apostolova LG, Salloway SP, Skovronsky DM. Donanemab in Early Alzheimer\u2019s Disease. N Engl J Med. 2021;384:1691\u2013704.","journal-title":"N Engl J Med"},{"key":"1236_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032014","volume":"7","author":"D Sehlin","year":"2012","unstructured":"Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Pettersson FE. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS ONE. 2012;7: e32014.","journal-title":"PLoS ONE"},{"key":"1236_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101665","volume":"181","author":"KB Johnsen","year":"2019","unstructured":"Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019;181: 101665.","journal-title":"Prog Neurobiol"},{"key":"1236_CR12","unstructured":"Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease."},{"key":"1236_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2013.10.061","volume":"81","author":"J Niewoehner","year":"2014","unstructured":"Niewoehner J, Bohrmann B, Collin L, Urich E, Sade H, Maier P, Rueger P, Stracke JO, Lau W, Tissot AC, Loetscher H, Ghosh A, Freskgard PO. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron. 2014;81:49\u201360.","journal-title":"Neuron"},{"key":"1236_CR14","doi-asserted-by":"crossref","unstructured":"Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, Dennis MS. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44.","DOI":"10.1126\/scitranslmed.3002230"},{"key":"1236_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.celrep.2017.12.019","volume":"22","author":"F Weber","year":"2018","unstructured":"Weber F, Bohrmann B, Niewoehner J, Fischer JAA, Rueger P, Tiefenthaler G, Moelleken J, Bujotzek A, Brady K, Singer T, Ebeling M, Iglesias A, Freskgard PO. Brain Shuttle Antibody for Alzheimer\u2019s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. Cell Rep. 2018;22:149\u201362.","journal-title":"Cell Rep"},{"key":"1236_CR16","doi-asserted-by":"publisher","first-page":"308","DOI":"10.7150\/thno.17155","volume":"7","author":"G Hultqvist","year":"2017","unstructured":"Hultqvist G, Syvanen S, Fang XT, Lannfelt L, Sehlin D. Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor. Theranostics. 2017;7:308\u201318.","journal-title":"Theranostics"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.118.213140","volume":"59","author":"SR Meier","year":"2018","unstructured":"Meier SR, Syvanen S, Hultqvist G, Fang XT, Roshanbin S, Lannfelt L, et al. Antibody-based in vivo PET imaging detects amyloid-beta reduction in Alzheimer transgenic mice after BACE-1 inhibition. J Nucl Med. 2018;59:1885\u201391.","journal-title":"J Nucl Med"},{"key":"1236_CR18","doi-asserted-by":"publisher","first-page":"302","DOI":"10.2967\/jnumed.121.262083","volume":"63","author":"SR Meier","year":"2022","unstructured":"Meier SR, Sehlin D, Roshanbin S, Falk VL, Saito T, Saido TC, Neumann U, Rokka J, Eriksson J, Syvanen S. (11)C-PiB and (124)I-Antibody PET Provide Differing Estimates of Brain Amyloid-beta After Therapeutic Intervention. J Nucl Med. 2022;63:302\u20139.","journal-title":"J Nucl Med"},{"key":"1236_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s40035-020-00214-1","volume":"9","author":"T Gustavsson","year":"2020","unstructured":"Gustavsson T, Syvanen S, O\u2019Callaghan P, Sehlin D. SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-beta antibody in a mouse model of Alzheimer\u2019s disease. Transl Neurodegener. 2020;9:37.","journal-title":"Transl Neurodegener"},{"key":"1236_CR20","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13195-018-0377-8","volume":"10","author":"S Syvanen","year":"2018","unstructured":"Syvanen S, Hultqvist G, Gustavsson T, Gumucio A, Laudon H, Soderberg L, Ingelsson M, Lannfelt L, Sehlin D. Efficient clearance of Abeta protofibrils in AbetaPP-transgenic mice treated with a brain-penetrating bifunctional antibody. Alzheimers Res Ther. 2018;10:49.","journal-title":"Alzheimers Res Ther"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.3390\/pharmaceutics14071412","volume":"14","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S, Julku U, Xiong M, Eriksson J, Masliah E, Hultqvist G, et al. Reduction of alphaSYN pathology in a mouse model of PD using a brain-penetrating bispecific antibody. Pharmaceutics. 2022;14:1412.","journal-title":"Pharmaceutics"},{"key":"1236_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.108985","volume":"208","author":"S Roshanbin","year":"2022","unstructured":"Roshanbin S, Xiong M, Hultqvist G, Soderberg L, Zachrisson O, Meier S, Ekmark-Lewen S, Bergstrom J, Ingelsson M, Sehlin D, Syvanen S. In vivo imaging of alpha-synuclein with antibody-based PET. Neuropharmacology. 2022;208: 108985.","journal-title":"Neuropharmacology"},{"key":"1236_CR23","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1021\/cn500105p","volume":"5","author":"P Nilsson","year":"2014","unstructured":"Nilsson P, Saito T, Saido TC. New mouse model of Alzheimer\u2019s. ACS Chem Neurosci. 2014;5:499\u2013502.","journal-title":"ACS Chem Neurosci"},{"key":"1236_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci. 2014;17:661\u20133.","journal-title":"Nat Neurosci"},{"key":"1236_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12987-021-00257-0","volume":"18","author":"R Faresjo","year":"2021","unstructured":"Faresjo R, Bonvicini G, Fang XT, Aguilar X, Sehlin D, Syvanen S. Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size. Fluids Barriers CNS. 2021;18:26.","journal-title":"Fluids Barriers CNS"},{"key":"1236_CR26","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1021\/mp400348n","volume":"10","author":"RK Sumbria","year":"2013","unstructured":"Sumbria RK, Hui EK, Lu JZ, Boado RJ, Pardridge WM. Disaggregation of amyloid plaque in brain of Alzheimer\u2019s disease transgenic mice with daily subcutaneous administration of a tetravalent bispecific antibody that targets the transferrin receptor and the Abeta amyloid peptide. Mol Pharm. 2013;10:3507\u201313.","journal-title":"Mol Pharm"},{"key":"1236_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000316530","volume":"8","author":"D Sehlin","year":"2011","unstructured":"Sehlin D, Hedlund M, Lord A, Englund H, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE. Heavy-Chain Complementarity-Determining Regions Determine Conformation Selectivity of Anti-A beta Antibodies. Neurodegener Dis. 2011;8:117\u201323.","journal-title":"Neurodegener Dis"},{"key":"1236_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s004180050266","volume":"110","author":"K Kissel","year":"1998","unstructured":"Kissel K, Hamm S, Schulz M, Vecchi A, Garlanda C, Engelhardt B. Immunohistochemical localization of the murine transferrin receptor (TfR) on blood-tissue barriers using a novel anti-TfR monoclonal antibody. Histochem Cell Biol. 1998;110:63\u201372.","journal-title":"Histochem Cell Biol"},{"key":"1236_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12575-017-0060-7","volume":"19","author":"XT Fang","year":"2017","unstructured":"Fang XT, Sehlin D, Lannfelt L, Syvanen S, Hultqvist G. Efficient and inexpensive transient expression of multispecific multivalent antibodies in Expi293 cells. Biol Proced Online. 2017;19:11.","journal-title":"Biol Proced Online"},{"key":"1236_CR30","doi-asserted-by":"crossref","unstructured":"Nielsen M, Lund O. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics. 2009;10:296.","DOI":"10.1186\/1471-2105-10-296"},{"key":"1236_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.neuroimage.2018.10.011","volume":"184","author":"XT Fang","year":"2019","unstructured":"Fang XT, Hultqvist G, Meier SR, Antoni G, Sehlin D, Syvanen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage. 2019;184:881\u20138.","journal-title":"Neuroimage"},{"key":"1236_CR32","doi-asserted-by":"crossref","unstructured":"Sehlin D, Syvanen S, faculty M. Engineered antibodies: new possibilities for brain PET? Eur J Nucl Med Mol Imaging. 2019;46:2848\u201358.","DOI":"10.1007\/s00259-019-04426-0"},{"key":"1236_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jalz.2012.11.005","volume":"9","author":"T Yang","year":"2013","unstructured":"Yang T, Hong S, O\u2019Malley T, Sperling RA, Walsh DM, Selkoe DJ. New ELISAs with high specificity for soluble oligomers of amyloid beta-protein detect natural Abeta oligomers in human brain but not CSF. Alzheimers Dement. 2013;9:99\u2013112.","journal-title":"Alzheimers Dement"},{"key":"1236_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s11307-021-01591-3","volume":"23","author":"SR Meier","year":"2021","unstructured":"Meier SR, Sehlin D, Hultqvist G, Syvanen S. Pinpointing Brain TREM2 Levels in Two Mouse Models of Alzheimer\u2019s Disease. Mol Imaging Biol. 2021;23:665\u201375.","journal-title":"Mol Imaging Biol"},{"key":"1236_CR35","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez JY, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"1236_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1042\/bj0890114","volume":"89","author":"FC Greenwood","year":"1963","unstructured":"Greenwood FC, Hunter WM, Glover JS. The Preparation of I-131-Labelled Human Growth Hormone of High Specific Radioactivity. Biochem J. 1963;89:114\u201323.","journal-title":"Biochem J"},{"key":"1236_CR37","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","volume":"36","author":"A Lord","year":"2009","unstructured":"Lord A, Gumucio A, Englund H, Sehlin D, Sundquist VS, Soderberg L, Moller C, Gellerfors P, Lannfelt L, Pettersson FE, Nilsson LN. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer\u2019s disease. Neurobiol Dis. 2009;36:425\u201334.","journal-title":"Neurobiol Dis"},{"key":"1236_CR38","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, Moller C, Tegerstedt K, Lord A, Laudon H, Sjodahl J, Soderberg L, Spens E, Sahlin C, Waara ER, Satlin A, Gellerfors P, Osswald G, Lannfelt L. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43:575\u201388.","journal-title":"J Alzheimers Dis"},{"key":"1236_CR39","doi-asserted-by":"crossref","unstructured":"Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, Jiang H, Kodira CD, de Lima KA, Herz J, Louveau A, Goldman DH, Salvador AF, Onengut-Gumuscu S, Farber E, Dabhi N, Kennedy T, Milam MG, Baker W, Smirnov I, Rich SS, Dominantly Inherited Alzheimer N, Benitez BA, Karch CM, Perrin RJ, Farlow M, Chhatwal JP, Holtzman DM, Cruchaga C, Harari O, Kipnis J. Meningeal lymphatics affect microglia responses and anti-Abeta immunotherapy. Nature. 2021;593:255\u201360.","DOI":"10.1038\/s41586-021-03489-0"},{"key":"1236_CR40","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12974-018-1134-4","volume":"15","author":"S Sollvander","year":"2018","unstructured":"Sollvander S, Nikitidou E, Gallasch L, Zysk M, Soderberg L, Sehlin D, Lannfelt L, Erlandsson A. The Abeta protofibril selective antibody mAb158 prevents accumulation of Abeta in astrocytes and rescues neurons from Abeta-induced cell death. J Neuroinflammation. 2018;15:98.","journal-title":"J Neuroinflammation"},{"key":"1236_CR41","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s13311-022-01283-y","volume":"19","author":"F Rofo","year":"2022","unstructured":"Rofo F, Meier SR, Metzendorf NG, Morrison JI, Petrovic A, Syvanen S, et al. A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in Alzheimer\u2019s disease mice. Neurotherapeutics. 2022;19:1588\u2013602.","journal-title":"Neurotherapeutics"},{"key":"1236_CR42","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41593-020-00737-w","volume":"23","author":"RE Uhlmann","year":"2020","unstructured":"Uhlmann RE, Rother C, Rasmussen J, Schelle J, Bergmann C, Ullrich Gavilanes EM, Fritschi SK, Buehler A, Baumann F, Skodras A, Al-Shaana R, Beschorner N, Ye L, Kaeser SA, Obermuller U, Christensen S, Kartberg F, Stavenhagen JB, Rahfeld JU, Cynis H, Qian F, Weinreb PH, Bussiere T, Walker LC, Staufenbiel M, Jucker M. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat Neurosci. 2020;23:1580\u20138.","journal-title":"Nat Neurosci"},{"key":"1236_CR43","doi-asserted-by":"crossref","unstructured":"Michno W, Stringer KM, Enzlein T, Passarelli MK, Escrig S, Vitanova K, et al. Following spatial Abeta aggregation dynamics in evolving Alzheimer's disease pathology by imaging stable isotope labeling kinetics. Sci Adv. 2021;7:eabg4855.","DOI":"10.1126\/sciadv.abg4855"},{"key":"1236_CR44","doi-asserted-by":"crossref","unstructured":"Stern AM, Yang Y, Meunier AL, Liu W, Cai Y, Ericsson M, et al. Abundant A\u03b2 fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer\u2019s disease brains. bioRxiv. 2022:10.18.512754.","DOI":"10.1101\/2022.10.18.512754"},{"key":"1236_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40629-020-00126-6","volume":"29","author":"A Gulsen","year":"2020","unstructured":"Gulsen A, Wedi B, Jappe U. Hypersensitivity reactions to biologics (part I): allergy as an important differential diagnosis in complex immune-derived adverse events. Allergo J Int. 2020;29:97\u2013125.","journal-title":"Allergo J Int"},{"key":"1236_CR46","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.3389\/fimmu.2020.01951","volume":"11","author":"A Vaisman-Mentesh","year":"2020","unstructured":"Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. Front Immunol. 2020;11:1951.","journal-title":"Front Immunol"},{"key":"1236_CR47","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1039\/D1CB00067E","volume":"2","author":"MLE Lundahl","year":"2021","unstructured":"Lundahl MLE, Fogli S, Colavita PE, Scanlan EM. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem Biol. 2021;2:1004\u201320.","journal-title":"RSC Chem Biol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01236-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-023-01236-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-023-01236-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T21:51:12Z","timestamp":1702331472000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-023-01236-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,2]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1186\/s13195-023-01236-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,2]]},"assertion":[{"value":"1 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments described in this study were approved by the Uppsala County Animal Ethics board (5.8.18\u201320401\/2020), following the rules and regulations of the Swedish Animal Welfare Agency and complied with the European Communities Council Directive of 22 September 2010 (2010\/63\/EU).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Hanna Laudon and Ken G Andersson are employees of BioArctic AB, Sweden. The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}